CSPC Innovation Pharmaceutical Co Ltd

CSPC Innovation Pharmaceutical Co Ltd has a liquidity risk score of medium, with a current ratio of 1.05 and a negative free cash flow of -990.92 million CNY, indicating limited short-term liquidity flexibility. The company's debt-to-equity ratio is 0.21, suggesting a relatively conservative capital structure, but its operating cash flow is negative at -195.69 million CNY, which raises concerns about its ability to service debt and fund operations without external financing. Profitability metrics are weak, with a return on equity of -9.04% and a return on assets of -3.84%, both significantly below the industry median for food processing companies. The company reported a net loss of 241.13 million CNY and an operating loss of 547.10 million CNY, indicating a challenging operating environment. Gross profit of 824.64 million CNY is insufficient to cover operating expenses, contributing to the net loss. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic downturns and regulatory changes. The absence of segment-specific revenue data limits the ability to assess the performance of individual product lines or markets. Looking ahead, the company is expected to face continued financial pressure. Revenue is projected to decline in the current fiscal year, with no clear signs of improvement in the next fiscal year. The capital expenditure of -568.39 million CNY suggests ongoing investment in infrastructure, but without a corresponding increase in revenue, this may further strain liquidity. The risk assessment highlights a key flag: net cash is negative after subtracting total debt, which increases the company's vulnerability to liquidity shocks. The dilution risk is currently low, but the company's negative free cash flow and operating losses may necessitate future equity or debt financing, which could dilute existing shareholders. Recent investor relations data shows a mixed analyst sentiment, with a mean recommendation of 1.25 (strong buy to hold) and a mean price target of 49.13 CNY. However, the absence of recent filings or transcripts limits the ability to assess management's strategic direction or operational updates.